1. Scrip

Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals

 
• By Deanna Kamienski

A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.

Start-Up Quarterly Statistics regular column feature image

Fourth quarter financings for biopharmaceutical start-ups totaled $2.73bn, including Relay Therapeutics 's $400m Series C venture capital round and Cerevel Therapeutics LLC's $350m Series A round.

Deals involving biopharma companies launched during the past four years included 34 partnerships and five acquisitions during the last three...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.